We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The COVID-19 pandemic in 2020 is a huge test and challenge to Chinese pharmaceutical enterprises. Some have forged ahead, while others have encountered disastrous defeats.